DEMSKI MARTHA J 4
4 · Equillium, Inc. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
DEMSKI MARTHA J
Director
Transactions
- Award
Director Stock Option (right to buy)
2025-02-14+12,000→ 12,000 totalExercise: $0.79Exp: 2029-06-10→ Common Stock (12,000 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2025-02-14−12,000→ 0 totalExercise: $6.01Exp: 2029-06-10→ Common Stock (12,000 underlying) - Award
Director Stock Option (right to buy)
2025-02-14+24,000→ 24,000 totalExercise: $0.79Exp: 2030-05-18→ Common Stock (24,000 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2025-02-14−24,000→ 0 totalExercise: $2.80Exp: 2030-05-18→ Common Stock (24,000 underlying) - Award
Director Stock Option (right to buy)
2025-02-14+20,770→ 20,770 totalExercise: $0.79Exp: 2031-05-25→ Common Stock (20,770 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2025-02-14−20,770→ 0 totalExercise: $6.55Exp: 2031-05-25→ Common Stock (20,770 underlying) - Award
Director Stock Option (right to buy)
2025-02-14+20,000→ 20,000 totalExercise: $0.79Exp: 2032-05-23→ Common Stock (20,000 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2025-02-14−20,000→ 0 totalExercise: $2.59Exp: 2032-05-23→ Common Stock (20,000 underlying)
Footnotes (5)
- [F1]The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
- [F2]On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.
- [F3]The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
- [F4]These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
- [F5]The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.